Clinical trial
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in…
NCT00171847 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00171847 |
|---|---|
| Title | Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer |
| Official title | An Open Label, Randomized Comparison of Femara® 2.5mg Once Daily With or Without Weekly Herceptin® Until Disease Progression as First-line Treatment in Postmenopausal Women With Advanced Breast Cancer. |
| Acronym | eLEcTRA |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | Roche - Prof. Dr. Jens Huober et al. |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Letrozole, Trastuzumab plus Letrozole |
| Enrollment | 93 |
| Start date | Mar 1, 2003 |
| Primary completion | Oct 1, 2008 |
| First posted | Sep 15, 2005 |
| Last update posted | Mar 31, 2010 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: